Dupixent® (dupilumab) is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid (bp) positive pivotal trial

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with dupixent than placebo

REGN Ratings Summary

REGN Quant Ranking